BenchSci, an AI software provider for biopharma research, has appointed Dr Mikael Dolsten as Chairman of its Board of Directors, effective June 2026. This marks the company's first Chairman role. Dr Dolsten joined BenchSci's board in July 2025, a year after retiring as Chief Scientific Officer and President of Pfizer Research & Development. During his 16 years at Pfizer, he oversaw approval of more than 36 medicines and vaccines. The appointment follows BenchSci's launch of EMET, an agentic research environment for preclinical R&D. Early results show 80% of EMET users report efficiency gains of up to 60%. BenchSci has raised over $200 million from investors including Generation Investment Management, Inovia Capital, and TCV. The platform is used by 16 top-20 pharmaceutical companies and over 4,500 research centres worldwide.

BenchSci extends ASCEND agreement with Merck. The renewed agreement supports Merck's efforts to integrate AI more deeply into its scientific workflows. BenchSci, a leading provider of AI software for biopharma research and development, renewed its two-year contract with Merck, known as MSD outside of the United States and Canada. The renewed agreement supports Merck's efforts to integrate AI more deeply into its scientific workflows. With ongoing access to ASCEND, scientists can more easily evaluate evidence and surface insights that inform early development decisions. BenchSci's ASCEND is the first neurosymbolic AI platform built to help biopharma understand disease biology at scale. At its core is the Biological Evidence Knowledge Graph (BEKG) - an experimentally grounded foundation that unifies diverse data sources, including peer-reviewed literature, multi-omics datasets, and clinical trial evidence. By combining the BEKG with advanced foundation models, ASCEND powers AI copilots and co-scientists that deliver rapid, explainable insights and enable faster, more confident research decisions. ASCEND also harmonizes each partner's internal data to create a secure, proprietary, and customized map of disease biology, forming a living, evolving foundation for discovery. "Seeing Merck's teams use ASCEND to unravel disease biology, strengthen hypotheses, and make more evidence-driven decisions underscores the real scientific value AI can deliver. This renewed agreement gives us the opportunity to deepen that impact and continue advancing how complex biological questions are explored in early discovery," said Liran Belenzon, CEO and Co-Founder, BenchSci.

BenchSci inks multi-year partnership with Mila to develop AI for drug discovery. Toronto-based BenchSci has teamed up with Montréal's AI research centre Mila to build artificial intelligence (AI) systems that can automatically create new scientific hypotheses and forecast the outcome of drug-related tests before they are conducted. BenchSci and Mila say this work could mark "a major step" on the path to autonomous drug discovery. Together, the two organizations hope to develop AI models capable of biological inference, or the ability to generate hypotheses and predictions for the outcomes of experiments during the drug discovery process. They are also targeting experimental assay prediction - which they say would mark "a major step" on the path to autonomous drug discovery. Experimental assay prediction forecasts the outcome of drug-related tests before they are conducted. BenchSci, which sells AI-powered software for biopharmaceutical research and development (R&D), says it has struck a multi-year partnership with Mila to "push the boundaries of predictive and generative modeling in drug discovery." In a statement, BenchSci co-founder and CEO Liran Belenzon argued that this could lay "the groundwork for autonomous labs that accelerate innovation, uncover insights beyond human reach, and bring life-saving medicines to patients faster." BenchSci will gain access to Government of Canada-backed Mila's network of AI experts, which will work alongside the company's team of machine learning scientists. Their combined research will help BenchSci evolve its generative AI R&D platform with new inference models that build on its existing map of disease biology. "By joining forces with BenchSci, we're applying world-class AI research to one of the most complex and impactful challenges of our time - understanding biology at a level that can transform how life-saving medicines are discovered and developed," Mila executive vice-president Stéphane Létourneau said in a statement. Founded in 2015, BenchSci aims to use AI to better understand disease biology for drug discovery. Its software acts as an AI R&D assistant for preclinical organizations. BenchSci says it caters to 16 of the top 20 pharma firms - from AbbVie to Gilead Sciences, Merck, Novartis, Novo Nordisk, and Sanofi - and more than 4,500 research centres globally. BenchSci has raised $218 million to fuel its efforts from a group of investors that includes Al Gore's Generation Investment Management, Inovia Capital, TCV, F-Prime, Gradient Ventures (Google's AI fund), and Golden Ventures. This Mila collaboration follows recent partnerships BenchSci secured with pharma giants Sanofi and Thermo Fisher Scientific. Generative AI has also impacted BenchSci's internal operations. As Belenzon wrote in a blog post this July, BenchSci shifted to an "AI-first" strategy in 2025. Similar to Canadian tech peers like Shopify and Klue, Belenzon wrote that BenchSci is now asking whether or not AI can do a job before it hires new employees. Since BenchSci's $95-million Series D in mid-2023, the company has cut down the size of its team, shedding 70 employees (then 17 percent of staff) in early 2024. It cut another 83 employees (23 percent of its overall workforce at the time) in 2025 in layoffs that were first reported by The Globe and Mail, since confirmed by BetaKit, as the company has adopted AI to slash costs. LinkedIn Insights indicates that BenchSci's headcount has fallen 35 percent over the past two years, to 292 today. This year, BenchSci has also made some changes to its leadership team. The company announced John Jackson as CTO and Peter Grandsard as fractional senior vice-president of strategy, while COO Eran Ben-Ari and director of product Nim Fox have left.